Clinical trials: Advanced Lymphoma
Advanced Solid Tumors, Lymphoma
Phase I Trial of PX-478
This study is being conducted to determine the safety and biologic activity of PX-478, and to allow for observation of any preliminary evidence of antitumor activity in patients with advanced metastatic cancer.
- Trial name
- NCT00522652
- Testing
- PX-478
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cascadian Therapeutics Inc.
Medical Oncology
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
To evaluate the effect of itraconazole or rifampin on the absorption, distribution, metabolism and elimination of COPANLISIB (BAY80-6946).
- Trial name
- NCT02253420
- Testing
- Copanlisib (BAY80-6946), Itraconazole, Rifampin
- Where
- 5 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Bayer
Solid Tumors, Acute Myeloid Leukemia
A Study of PLX51107 in Advanced Malignancies
The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced…
- Conditions
- Solid Tumors, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02683395
- Testing
- PLX51107
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Plexxikon
Advanced Cancer
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
WXFL10030390 (WX390) is a novel oral small molecular that inhibits phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) and has demonstrated potent inhibitory effects on multiple human tumor xenografts.
- Trial name
- NCT03730142
- Testing
- WXFL10030390
- Where
- China
- Volunteers
- 82 people
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
Lymphoma, Multiple Myeloma
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood cancers: relapsed or refractory (R/R) lymphoma multiple myeloma newly diagnosed…
- Conditions
- Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03530683
- Testing
- Maplirpacept (PF-07901801), Azacitidine, Venetoclax
- Where
- 62 sites in United States
- Volunteers
- 189 people
- Sponsor
- Pfizer
Solid Tumor, Adult, Head and Neck Cancer
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced…
- Conditions
- Solid Tumor, Adult, Head and Neck Cancer, Non Small Cell Lung Cancer, Diffuse Large B Cell Lymphoma
- Trial name
- NCT03543813
- Testing
- CX-2029
- Where
- 25 sites in United States, South Korea and 2 more
- Volunteers
- 133 people
- Sponsor
- CytomX Therapeutics
Breast Cancer, Non-small Cell Lung Cancer
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
This study was a randomized, single dose crossover comparison of the investigational product with a Reference Product (vinorelbine tartrate injection, NAVELBINE®).
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Non-Hodgkins Lymphoma
- Trial name
- NCT00432562
- Testing
- Vinorelbine Tartrate
- Where
- 5 sites in Argentina
- Volunteers
- 31 people
- Sponsor
- Mast Therapeutics, Inc.
Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies…
- Conditions
- Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma
- Trial name
- NCT01421524
- Testing
- CC-122
- Where
- 39 sites in United States, Belgium and 3 more
- Volunteers
- 271 people
- Sponsor
- Celgene